Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Cardiovascular Translational Research|June 2, 2017
Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)Sylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Biomedicines|October 28, 2023
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle CellsChristopher D Sarsons, Dean Gilham, Laura M Tsujikawa, et al.
Pharmacology Research & Perspectives|April 13, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapyLi Fu, Sylwia Wasiak, Laura M Tsujikawa, et al.
International Immunopharmacology|March 1, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammationLi Fu, Dean Gilham, Stephanie C Stotz, et al.
Kidney International Reports|June 2, 2018
Benefit of Apabetalone on Plasma Proteins in Renal DiseaseSylwia Wasiak, Laura M Tsujikawa, Christopher Halliday, et al.
Biomedicines|June 28, 2023
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal ImpairmentDean Gilham, Sylwia Wasiak, Brooke D Rakai, et al.
Atherosclerosis|February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular diseaseDean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Data in Brief|August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytesSylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Atherosclerosis|November 27, 2018
Apabetalone downregulates factors and pathways associated with vascular calcificationDean Gilham, Laura M Tsujikawa, Christopher D Sarsons, et al.
Cardiovascular Therapeutics|August 22, 2020
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response <i>In Vitro</i>, in Mice and in Patients with Cardiovascular DiseaseSylwia Wasiak, Dean Gilham, Emily Daze, et al.
Pageof 2